[50] Therefore, we speculate that differential protein interacting capabilities of the b3a2 and b2a2 fusion proteins may alter either expression or stability of Separase in IM treated CML cells. The gene discussed is ESPL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.